- Tags: thyroid eye disease (TED)
Research
Researchers identify higher post-cataract TED risk in patients with thyroid disease
Patients demonstrate up to 51% higher risk of developing TED in the year after surgery, with hyperthyroid patients facing more than double the risk.
Pipeline
Genentech's sBLA for subcutaneous TED therapy receives FDA priority review
Enspryng (satralizumab) has the potential to become the first at-home SC therapy to target the underlying disease with a novel mechanism of action.
Products
FDA clears Viridian's veligrotug for TED as Lumvoa
Lumvoa (veligrotug-vvze) will launch immediately as he second FDA-approved TED treatment—and the first with labeling for both active and chronic TED.
Pipeline
Ethyreal Bio debuts with $101M in funding to advance TED therapy
Biotech company emerges from stealth with Series B financing supporting FIH trial initiation for ETHY-001, an anti-TSHR antibody for TED and Graves’ disease.
Pipeline
Viridian Therapeutics releases topline phase 3 TED data elegrobart
Subcutaneous IGF-IR has potential to be the first autoinjector treatment for TED; BLA submission on track for Q1 2027
Research
Real-world TED data finds disease advances beyond acute phase
Real-world study demonstrates heterogeneous disease progression in TED, challenging the traditional self-limited paradigm.
Research
TEPEZZA on-body injector demonstrates positive phase 3 performance for TED
FDA-approved therapy administered subcutaneously met its primary endpoint in demonstrating a statistically significant and clinically meaningful 77% PRR.
Pipeline
Viridian releases phase 3 topline data on elegrobart for TED
REVEAL-1 meets primary goals, with the subcutaneous IGF-1R monoclonal antibody showing rapid and clinically meaningful reductions in proptosis and diplopia.
Research
TED may cause reduced stromal corneal thickness
Study findings indicate association with layer-specific corneal structural changes.
Pipeline
FDA accepts Viridian's veligrotug BLA for TED
Therapeutic also receives priority review, enabling a PDUFA target action date for the end of June 2026.Pipeline
Viridian submits BLA for veligrotug to treat TED
Company is requesting Priority Review of veli, an IGF-1R monoclonal antibody intravenously-administered to treat chronic TED.
Pipeline
Viridian reports long-term durability data, secures FDA designation for TED therapy
After receiving FDA Breakthrough Therapy designation, new 52-week data finds 70% of proptosis responders at Week 15 maintained their response.
Pipeline
Sling Therapeutics reports positive phase 2b/3 data on oral small molecule for TED
LIDS trial of linsitinib meets primary endpoint in meeting a statistically significant proptosis responder rate for patients.
Research
Could tamsulosin be effective for TED-related eyelid symptoms?
Oral tamsulosin demonstrates safety and efficacy in TED patients with upper eyelid retraction.
Pipeline
Acelyrin announces phase 2 data and phase 3 design for TED therapy
Clinical findings support lonigutamab as the first subcutaneous anti-IGF-1R to demonstrate robust efficacy in TED patients comparable to IV-administered standard of care.Pipeline
Viridian reports positive phase 3 data on veligrotug for chronic TED
Latest THRIVE-2 study findings detail a favorable safety profile, shorter dosing regimen, and a promising diplopia response and resolution rate.
Pipeline
Viridian reports positive topline data from phase 3 TED trial
VRDN-001 (now veligrotug) achieves all primary and secondary endpoints as company plans to submit a BLA in 2025.
Pipeline
Viridian completes patient enrollment for THRIVE-2 chronic TED trial
Second phase 3 trial in the IGF-IR pipeline is evaluating VRDN-001, previously reported to reduce disease signs and symptoms after just two infusion sessions.
Pipeline
Viridian to initiate two phase 3 studies for chronic TED
VRDN-003, an IGF-IR monoclonal antibody, will be evaluated as a subcutaneous injection administered every 4 or 8 weeks.
Research